FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 328:560-565 February 25, 1993 Number 8 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Radiotherapy is curative for localized Hodgkin's disease,^1,2 and there is now general agreement that advanced Hodgkin's disease can be cured by chemotherapy. This opinion is bolstered by the 20-year survival experience of the original group of patients treated with combination chemotherapy at the National Cancer Institute (Figure 1) and by experience with other regimens (Table 1) ^{2,3,4,5,6,7,8,9}.

View larger version (13K): [in this window] [in a new window]   Figure 1. Survival of 188 Patients with Hodgkin's Disease Treated with MOPP (Mechlorethamine, Vincristine, Procarbazine, and Prednisone). Circles denote patients who relapsed, and vertical lines patients without a relapse. Reprinted from Longo et al.4 with the permission of the publisher.

 

View this table: [in this window] [in a new window]   Table 1. Commonly . . . [Full Text of this Article]

 
Therapy According to Disease Stage

Selecting a Chemotherapy Program

Salvage Treatment

Conclusions

Source Information

From the Memorial Sloan-Kettering Cancer Center, New York (V.T.D.), and the National Cancer Institute, Bethesda, Md. (S.M.H.).

Address reprint requests to Dr. DeVita at the Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

References

Related Letters:

Hodgkin's Disease
Perez E. A., Rosenthal S. A., DeVita V. T., Hubbard S. M.
Extract | Full Text  
N Engl J Med 1993; 329:361-362, Jul 29, 1993. Correspondence

This article has been cited by other articles:

• Sahin, U., Koslowski, M., Dhaene, K., Usener, D., Brandenburg, G., Seitz, G., Huber, C., Tureci, O. (2008). Claudin-18 Splice Variant 2 Is a Pan-Cancer Target Suitable for Therapeutic Antibody Development. Clin. Cancer Res. 14: 7624-7634 [Abstract] [Full Text]  
• Bredenfeld, H., Franklin, J., Nogova, L., Josting, A., Fries, S., Mailander, V., Oertel, J., Diehl, V., Engert, A. (2004). Severe Pulmonary Toxicity in Patients With Advanced-Stage Hodgkin's Disease Treated With a Modified Bleomycin, Doxorubicin, Cyclophosphamide, Vincristine, Procarbazine, Prednisone, and Gemcitabine (BEACOPP) Regimen Is Probably Related to the Combination of Gemcitabine and Bleomycin: A Report of the German Hodgkin's Lymphoma Study Group. JCO 22: 2424-2429 [Abstract] [Full Text]  
• Montalban, C., Garcia, J. F., Abraira, V., Gonzalez-Camacho, L., Morente, M. M., Bello, J. L., Conde, E., Cruz, M. A., Garcia-Sanz, R., Garcia-Larana, J., Grande, C., Llanos, M., Martinez, R., Flores, E., Mendez, M., Ponderos, C., Rayon, C., Sanchez-Godoy, P., Zamora, J., Piris, M. A. (2004). Influence of Biologic Markers on the Outcome of Hodgkin's Lymphoma: A Study by the Spanish Hodgkin's Lymphoma Study Group. JCO 22: 1664-1673 [Abstract] [Full Text]  
• Baetz, T., Belch, A., Couban, S., Imrie, K., Yau, J., Myers, R., Ding, K., Paul, N., Shepherd, L., Iglesias, J., Meyer, R., Crump, M. (2003). Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group. Ann Oncol 14: 1762-1767 [Abstract] [Full Text]  
• Kiani, B., Magro, C. M., Ross, P. Jr (2003). Endobronchial presentation of Hodgkin lymphoma: a review of the literature. Ann. Thorac. Surg. 76: 967-972 [Abstract] [Full Text]  
• Schnell, R., Staak, O., Borchmann, P., Schwartz, C., Matthey, B., Hansen, H., Schindler, J., Ghetie, V., Vitetta, E. S., Diehl, V., Engert, A. (2002). A Phase I Study with an Anti-CD30 Ricin A-Chain Immunotoxin (Ki-4.dgA) in Patients with Refractory CD30+ Hodgkin's and Non-Hodgkin's Lymphoma. Clin. Cancer Res. 8: 1779-1786 [Abstract] [Full Text]  
• Tesch, H., Diehl, V., Lathan, B., Hasenclever, D., Sieber, M., Ruffer, U., Engert, A., Franklin, J., Pfreundschuh, M., Schalk, K.P., Schwieder, G., Wulf, G., Dolken, G., Worst, P., Koch, P., Schmitz, N., Bruntsch, U., Tirier, C., Muller, U., Loeffler, M. (1998). Moderate Dose Escalation for Advanced Stage Hodgkin's Disease Using the Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, Procarbazine, and Prednisone Scheme and Adjuvant Radiotherapy: A Study of the German Hodgkin's Lymphoma Study Group. Blood 92: 4560-4567 [Abstract] [Full Text]  
• Multani, P. S., Grossbard, M. L. (1996). Staging Laparotomy in the Management of Hodgkin's Disease: Is it Still Necessary?. The Oncologist 1: 41-55 [Abstract] [Full Text]  
• Perez, E. A., Rosenthal, S. A., DeVita, V. T., Hubbard, S. M. (1993). Hodgkin's Disease. NEJM 329: 361-362 [Full Text]